CD276 and pancreatic adenocarcinoma: Patients with low-risk PAAD presented markedly higher expression levels of BTLA, CD27, CTLA4, and PD-1, and lower expression levels of CD47, PD-L1, CD276, and VTCN1 (Fig. 6B, D).